ABT-143 + ABT-335 + Rosuvastatin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adverse Events
Conditions
Adverse Events, Pharmacokinetic
Trial Timeline
May 1, 2008 → —
NCT ID
NCT00681395About ABT-143 + ABT-335 + Rosuvastatin
ABT-143 + ABT-335 + Rosuvastatin is a phase 1 stage product being developed by AstraZeneca for Adverse Events. The current trial status is completed. This product is registered under clinical trial identifier NCT00681395. Target conditions include Adverse Events, Pharmacokinetic.
What happened to similar drugs?
1 of 2 similar drugs in Adverse Events were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00808678 | Phase 1 | Completed |
| NCT00826358 | Phase 1 | Completed |
| NCT00681395 | Phase 1 | Completed |
Competing Products
7 competing products in Adverse Events
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABT-143 + ABT-335 and rosuvastatin | AstraZeneca | Phase 1 | 29 |
| Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo | AstraZeneca | Phase 1 | 21 |
| AZD1222 | AstraZeneca | Pre-clinical | 26 |
| dupilumab | Sanofi | Pre-clinical | 33 |
| Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine | Sanofi | Phase 1 | 29 |
| ACAM2000 | Emergent BioSolutions | Phase 3 | 30 |
| Vaccination with ACAM2000 | Emergent BioSolutions | Approved | 33 |